헬스케어 웨어러블 로봇 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the healthcare wearable robots market size is projected to expand from USD 3.28 billion in 2025 and USD 3.62 billion in 2026 to USD 5.94 billion by 2031, registering a CAGR of 10.41% between 2026 to 2031.

This report is Segmented by Body Region (Lower-Limb, and More), Frame Type (Rigid Exoskeletons, Soft Exosuits), Clinical Application (Stroke, Spinal Cord Injury, and More), End User (Hospitals, and More), Actuation Type (Electric Motor, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Healthcare Wearable Robots Market Trends and Insights

Aging-Related Neuro-Musculoskeletal Impairment Prevalence

The World Health Organization recorded 1.71 billion people living with neuro-musculoskeletal disorders in 2024, a 12% rise since 2019. Japan subsidizes exoskeleton costs for elder-care facilities, spurring 400 CYBERDYNE HAL deployments by December 2024 . Germany followed suit in 2024 when statutory insurance began covering robotic gait therapy, driving Ottobock C-Brace orders up significantly year over year. Prevalence climbs non-linearly after age 75, concentrating demand in super-aged societies such as Japan, Italy, and Germany. Because U.S. skilled-nursing care costs USD 80,000-120,000 annually, a USD 100,000 exoskeleton has a 1.2-year payback, locking in long-run demand even if device prices soften.

Expanding Regulatory Clearances and Clinical Indications

The FDA granted 510(k) clearances to CYBERDYNE's HAL small model, ReWalk 7, and Wandercraft's Atalante X between May 2024 and October 2025, showing the agency's growing comfort with exoskeleton safety profiles. CYBERDYNE's May 2024 clearance added pediatric and rare-disease indications, expanding the treatable addressable population. CE-mark approvals after the tougher EU MDR rules prove that robust clinical files can still move through Europe in roughly 18 months . China sliced its approval timeline to 18 months in 2024, allowing local vendors to win share across Asia before Western incumbents secure registration. Each successive approval supplies post-market data that shortens review cycles for follow-on submissions, reinforcing the positive loop.

High Device, Service, and Training Costs

Exoskeleton price tags span USD 70,000-150,000, while annual service contracts add USD 8,000-12,000, pushing the five-year total cost of ownership to as much as USD 180,000. The majority of U.S. rehab hospitals flagged sticker shock as the top hurdle in a 2024 APTA poll, and 41% cited 40-hour therapist training requirements. Leasing eases capex pressure; CYBERDYNE's 2024 pact with Mitsubishi UFJ Lease prices HAL access at JPY 150,000 (USD 1,000) per month, a model now mirrored by ReWalk and Wandercraft. In India, locally assembled devices sell for USD 30,000-50,000, yet adoption lags because out-of-pocket costs exceed average household income for the majority of candidates. Medicare's 80% coverage erases most financial friction in the United States, but only 30% of European private insurers reimbursed exoskeleton therapy as of 2024, prolonging payback horizons.

Other drivers and restraints analyzed in the detailed report include:

1. Strengthening Clinical Evidence for Functional Recovery & ADL Gains
2. Emerging Reimbursement Pathways and Coverage Pilots
3. Safety, Supervision, and Liability Constraints in Real-World Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Lower-limb systems accounted for 58.9% of the healthcare wearable robots market share in 2025, owing to their entrenched use in spinal cord injury rehabilitation. The healthcare wearable robots market size for upper-limb devices is projected to expand at a 10.96% CAGR through 2031, as evidence mounts that robotic arm therapy increases Fugl-Meyer scores by 12 points in eight weeks. Trunk and full-body variants meet a separate need for postural stability for elderly users, and Honda placed 50 Walking Assist devices in Japanese care homes in 2024.

While lower-limb therapy delivers milestone gains up to community ambulation, upper-limb platforms continue adding value by tackling fine-motor recovery, extending the revenue window per patient. Pediatric indications opened by CYBERDYNE's small HAL clearances enlarge the addressable base, especially for cerebral palsy. Hospitals now procure mixed portfolios to align device geometry with diagnosis, and vendors that master modular architectures can address multiple body regions without redesigning core electronics.

Rigid architectures held 58.96% of 2025 revenue because their 40 Nm knee torque accommodates users with complete motor loss. However, the healthcare wearable robots market size for soft exosuits is tracking an 11.13% CAGR as pneumatic muscles and Bowden cables slash frame weight significantly and enable 8-hour wear periods.

Functionally, rigid frames remain the gold standard for inpatient SCI therapy, yet soft exosuits dominate home-care adoption where comfort and fast donning beat raw power. Ottobock's hybrid Paexo proves the segments will blend: its 25 Nm output bridges the gap and drew 28% higher 2024 orders from European rehab centers. ISO 13482 certification is becoming a marketing prerequisite, and soft-exuit makers that clear the bar early will ride accelerated direct-to-consumer channels.

Geography Analysis

North America generated 41.6% of 2025 sales and is advancing at a 10.81% CAGR because CMS's lump-sum payment slashed out-of-pocket costs from USD 100,000 to roughly USD 20,000 for Medicare beneficiaries. The Veterans Affairs program placed 500 units for home therapy in 2024, and 340 U.S. hospitals now offer robotic gait services, up from 200 in 2022. Canada and Mexico launched provincial and federal pilots in 2024-2025, signaling continent-wide momentum for reimbursement.

Europe held a significant share of 2025 revenue and is rising at a notable CAGR despite heterogeneous payer policies. Germany's 2024 green light for robotic gait therapy lifted Ottobock orders significantly, while CYBERDYNE and ReWalk both navigated the stricter EU MDR to secure CE marks. U.K. tele-rehab pilots achieved better completion rates, but the lack of French reimbursement and fragmented Southern European funding are restraining broader penetration.

Asia-Pacific is expected to register significant growth over the forecasted period. Japan's super-aged demographics and subsidy scheme drove 400 HAL installs by late 2024. China cut approval times in half and backed local manufacturing with a USD 2 billion fund, allowing Angel Robotics and Fourier Intelligence to notably undercut Western pricing. Australia's NDIS and South Korea's stroke pilots widen Oceania access, while India remains price-constrained until a national payer plan materializes.

The Middle East & Africa and South America accounted for a modest share of 2025 consumption and posted notable growth. The UAE and South Africa launched limited pilots, but widespread uptake hinges on private insurance participation and philanthropic grants, as public budgets remain focused on primary care.

1. Able Human Motion S.L.
2. Angel Robotics Co., Ltd.
3. Biomotum, Inc.
4. B-Temia
5. Cyberdyne
6. Daiya Industry Co., Ltd.
7. Ekso Bionics Holdings, Inc.
8. ExoAtlet Global SA
9. Exosystems Inc.
10. Fourier Intelligence Co., Ltd.
11. Gogoa Mobility Robots S.L.
12. Hangzhou RoboCT Technology Development Co., Ltd
13. Honda Motor Co., Ltd.
14. Lifeward Ltd
15. Marsi Bionics S.L.
16. Myomo, Inc.
17. MyoSwiss AG
18. Ottobock
19. Roam Robotics, Inc.
20. Technaid S.L.
21. Wandercraft SAS

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Aging-Related Neuro-Musculoskeletal Impairment Prevalence
  • 4.2.2 Expanding Regulatory Clearances and Clinical Indications
  • 4.2.3 Strengthening Clinical Evidence for Functional Recovery & ADL Gains
  • 4.2.4 Emerging Reimbursement Pathways and Coverage Pilots
  • 4.2.5 Miniaturized Soft Exosuits Enabling Home Use and Continuous Therapy
  • 4.2.6 Tele-Rehab Integration and Outcomes-Linked Contracting
• 4.3 Market Restraints
  • 4.3.1 High Device, Service, and Training Costs
  • 4.3.2 Safety, Supervision, and Liability Constraints in Real-World Use
  • 4.3.3 Lack of Standardized Outcomes Hindering Broad Reimbursement
  • 4.3.4 Precision Component Supply Constraints
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Body Region
  • 5.1.1 Lower-limb
  • 5.1.2 Upper-limb
  • 5.1.3 Trunk/Full-body
• 5.2 By Frame Type
  • 5.2.1 Rigid exoskeletons
  • 5.2.2 Soft exosuits
• 5.3 By Clinical Application
  • 5.3.1 Stroke
  • 5.3.2 Spinal cord injury
  • 5.3.3 Multiple sclerosis
  • 5.3.4 Cerebral palsy & pediatrics
  • 5.3.5 Orthopedic & post-surgical rehab
  • 5.3.6 Elderly mobility assistance
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Rehabilitation centers
  • 5.4.3 Homecare
• 5.5 By Actuation Type
  • 5.5.1 Electric motor
  • 5.5.2 Pneumatic
  • 5.5.3 Hybrid/cable-driven
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Able Human Motion S.L.
  • 6.3.2 Angel Robotics Co., Ltd.
  • 6.3.3 Biomotum, Inc.
  • 6.3.4 B-Temia Inc.
  • 6.3.5 Cyberdyne Inc.
  • 6.3.6 Daiya Industry Co., Ltd.
  • 6.3.7 Ekso Bionics Holdings, Inc.
  • 6.3.8 ExoAtlet Global SA
  • 6.3.9 Exosystems Inc.
  • 6.3.10 Fourier Intelligence Co., Ltd.
  • 6.3.11 Gogoa Mobility Robots S.L.
  • 6.3.12 Hangzhou RoboCT Technology Development Co., Ltd
  • 6.3.13 Honda Motor Co., Ltd.
  • 6.3.14 Lifeward Ltd
  • 6.3.15 Marsi Bionics S.L.
  • 6.3.16 Myomo, Inc.
  • 6.3.17 MyoSwiss AG
  • 6.3.18 Ottobock SE & Co. KGaA
  • 6.3.19 Roam Robotics, Inc.
  • 6.3.20 Technaid S.L.
  • 6.3.21 Wandercraft SAS

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment